emanuela sant'antonio

@hsr.it

Hematology Consultant, Division of Experimental Oncology
IRCCS Ospedale San Raffaele

emanuela sant'antonio


               Download Compact PDF  
https://researchid.co/emanuela_santantonio

RESEARCH, TEACHING, or OTHER INTERESTS

Hematology
38

Scopus Publications

5674

Scholar Citations

21

Scholar h-index

28

Scholar i10-index

Scopus Publications

  • Monoclonal B-Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect
    Andrea Serafin, Emanuela Sant’Antonio, Fabrizio Mavilia, Francesca Gandini, Stefano De Pretis, Lydia Scarfò, Paolo Ghia
    Hematological Oncology, 2025
    Monoclonal B‐cell lymphocytosis (MBL) is a hematologic condition defined by the presence of a small clonal B‐cell population in the peripheral blood, without clinical or laboratory evidence of lymphoproliferative disorders. It is classified into low‐count (LC‐MBL) and high‐count (HC‐MBL) subtypes based on clonal size. HC‐MBL shares genetic and biological features with early‐stage chronic lymphocytic leukemia (CLL), has a well‐established 1%–2% annual risk of progression, and is associated with an increased risk of infections, second malignancies and a reduced response to vaccines due to immune dysfunction. LC‐MBL, on the other hand, is a distinct entity with a lower likelihood of progression, but its potential impact on immune function remains unclear. While some studies suggest an association with increased infection risk and immune alterations, further research is needed to clarify its clinical significance. Beyond the risk of progression, MBL is increasingly recognized as a condition requiring careful management due to its broader implications on immune function and cancer susceptibility. Given these risks, preventive strategies are essential for all individuals with MBL, including adherence to cancer screening programs, vaccinations, smoking cessation, sun protection, and a healthy lifestyle to mitigate potential complications.
  • Loss of CYLD promotes splenic marginal zone lymphoma
    Athanasios Pseftogas, Jessica Bordini, Silvia Heltai, Ferdinando Bonfiglio, Georgios Gavriilidis, Vasileios Vasileiou, Sofoklis Keisaris, Daniela Belloni, Caterina Taccetti, Pamela Ranghetti, Eleonora Perotta, Michela Frenquelli, Uday Aditya Sarkar, Elisa Albi, Francesca Martini, Emmanuela Sant'Antonio, Fabrizio Mavilia, Fotis Psomopoulos, Manasori Daibata, José Ángel Martínez Climent, George Mosialos, Davide Rossi, Alessandro Campanella, Lydia Scarfò, Kostas Stamatopoulos, Konstantinos Xanthopoulos, Paolo Ghia
    Hemasphere, 2025
    Splenic marginal zone lymphoma (SMZL) is a distinct clinical and pathological entity among marginal zone lymphomas. Genetic and microenvironmental factors leading to aberrant activation of the NF‐κB pathway have been implicated in SMZL pathogenesis. CYLD is a negative regulator of NF‐κB and other signaling pathways acting as a deubiquitinase of regulatory molecules and has been reported as a tumor suppressor in different types of cancer, including B‐cell malignancies. To assess whether CYLD is implicated in the natural history of SMZL, we profiled primary cells from patients with SMZL and SMZL cell lines for CYLD expression and functionality. We report that CYLD is downregulated in patients with SMZL and that CYLD ablation in vitro leads to NF‐κB pathway hyperactivation, promoting the proliferation of SMZL cells. In addition, we found that CYLD deficiency was associated with increased migration of SMZL cells in vitro, through CCR7 receptor signaling, and with increased dissemination in vivo. CYLD loss was sufficient to induce BcR signaling, conferring increased resistance to ibrutinib treatment in vitro. In summary, our work uncovers a novel role of CYLD as a key regulator in SMZL pathogenesis, dissemination, and resistance to targeted agents. On these grounds, CYLD could be proposed as a novel target for patient stratification and personalized interventions.
  • Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
    A. Campanella, A. Capasso, S. Heltai, C. Taccetti, E. Albi, Y. Herishanu, S. Haggenburg, T. Chatzikonstantinou, M. Doubek, M. Kättström, K. Giannopoulos, M. Simkovic, C. Moreno, M. Massaia, H. Bumbea, S. Alshemmari, P. Ranghetti, E. Perotta, F. Martini, E. Sant'Antonio, M. Colia, C. Combi, S. Levi, A. P. Kater, M. Hazenberg, I. S. Nijhof, Q. Hofsink, C. Demosthenous, J. Kotaskova, J. Zaleska, F. Vrbacky, A. Mora Raya, D. Bisogno, I. E. Tripoli, V. M. Popov, V. Roman, N. Stavroyianni, M. Karypidou, E. Scarano, M. Locatelli, M. Frenquelli, L. Scarfò, K. Stamatopoulos, P. Ghia
    American Journal of Hematology, 2024
    Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.
  • Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network)
    Emanuele Cencini, Ilaria Romano, Francesco Ghio, Chiara Camerini, Ilaria Bertaggia, Roberta Giachetti, Lara Mannelli, Maria Teresa Pirrotta, Giulia Lucco Navei, Manuel Ciceri, Giulia Cervetti, Emanuela Sant’Antonio, Federico Simonetti, Silvia Birtolo, Benedetta Puccini, Monica Bocchia, Alberto Fabbri
    Annals of Hematology, 2023
  • Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project
    Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A. Palumbo, Francesco Mannelli, Valerio De Stefano, Marco Ruggeri, Elena M. Elli, Roberta Zanotti, Oscar Borsani, Irene Bertozzi, Andrea Duminuco, Silvia Betti, Giuseppe Carli, Fabrizio Cavalca, Ilaria Tanasi, Elisa Rumi, Maria L. Randi, Bruno Garibaldi, Giuseppe G. Loscocco, Paola Guglielmelli, Alessandro M. Vannucchi
    Cancer Medicine, 2023
    BACKGROUND Incorporating real-world data in the drug development process allows the improvement of health outcomes by providing better representation of actual patterns of drug safety and efficacy. AIMS AND METHODS Here, we present the results of a retroprospective, observational real-life study of 154 patients with myelofibrosis treated with ruxolitinib in a real-life setting in seven Italian centers of the MYNERVA project. RESULTS Median drug exposure was 29 (range, 3-98) months. Discontinuation rate was 27% after a median time of 13 (range, 3-61). While hematological toxicities were in line with previous findings, infections occurred frequently, representing a not negligible cause of discontinuation and death. Anemia, symptoms, and spleen responses were obtained at any time in 23%, 91%, and 68% of patients, respectively; most patients achieved their responses by week 24. Larger splenomegaly and delayed treatment initiation correlated with lower spleen response at 24 weeks. Spleen response was associated with a superior overall survival, regardless of DIPSS. Of interest, both achievement and loss of spleen response had prognostic implications. DISCUSSION AND CONCLUSION Overall, our findings provide insights on the efficacy and safety of ruxolitinib in a real-world, multicenter cohort of Italian MF patients.
  • CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
    Antonella Capasso, Elisa Albi, Luana Schiattone, Francesca Martini, Emanuela Sant'Antonio, Lydia Scarfò, Pamela Ranghetti, Michela Frenquelli, Alessandro Campanella, Eleonora Perotta, Silvia Heltai, Maria Colia, Paolo Ghia
    Clinical Lymphoma Myeloma and Leukemia, 2022
  • Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
    Massimo Breccia, Francesca Palandri, Paola Guglielmelli, Giuseppe Alberto Palumbo, Alessandra Malato, Francesco Mendicino, Alessandra Ricco, Emanuela Sant’Antonio, Mario Tiribelli, Alessandra Iurlo
    Current Oncology, 2022
    The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptoms responses, improved quality of life, and overall survival. Despite this, several unmet needs remain, including the absence of resistance criteria, suboptimal response, the timing of allogeneic transplant, and the management of patients in case of intolerance. Here, we report the results of the second survey led by the “MPN Lab” collaboration, which aimed to report physicians’ perspectives on these topics. As in our first survey, physicians were selected throughout Italy, and we included those with extensive experience in treating myeloproliferative neoplasms and those with less experience representing clinical practice in the real world. The results presented here, summarized using descriptive analyses, highlight the need for a clear definition of response to ruxolitinib as well as recommendations to guide the management of ruxolitinib under specific conditions including anemia, thrombocytopenia, infections, and non-melanoma skin cancers.
  • Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
    Oscar Borsani, Paul Bastard, Jérémie Rosain, Adrian Gervais, Emanuela Sant’Antonio, Daniele Vanni, Ilaria Carola Casetti, Daniela Pietra, Chiara Trotti, Silvia Catricalà, Virginia Valeria Ferretti, Luca Malcovati, Luca Arcaini, Jean-Laurent Casanova, Alessandro Borghesi, Elisa Rumi
    Blood, 2022
    International audience
  • New Insights into Neuropeptides Regulation of the Immune System and Hemopoiesis: Effects on Hematologic Malignancies
    Alessandro Allegra, Emanuela Sant’Antonio, Caterina Musolino, Roberta Ettari
    Current Medicinal Chemistry, 2022
    :Several neurotransmitters and neuropeptides were reported to join to or to cooperate with different cells of the immune system, bone marrow, and peripheral cells and numerous data support that neuroactive molecules might control immune system activity and hemopoiesis operating on lymphoid organs, and the primary hematopoietic unit, the hematopoietic niche. Furthermore, many compounds seem to be able to take part to the leukemogenesis and lymphomagenesis process, and in the onset of multiple myeloma. In this review, we will assess the possibility that neurotransmitters and neuropeptides may have a role in the onset of haematological neoplasms, may affect the response to treatment or may represent a useful starting point for a new therapeutic approach. More in vivo investigations are needed to evaluate neuropeptide’s role in haematological malignancies and the possible utilization as an antitumor therapeutic target. Comprehending the effect of the pharmacological administration of neuropeptide modulators on hematologic malignancies opens up new possibilities in curing clonal hematologic diseases to achieve more satisfactory outcomes.
  • Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy
    Emanuela Sant'Antonio, Oscar Borsani, Chiara Camerini, Cirino Botta, Marco Santoro, Alessandro Allegra, Sergio Siragusa
    Blood Reviews, 2022
  • Unusual presentation of extranodal diffuse large B-cell lymphoma in a solid-organ recipient during long-term immunosuppressive treatment
    Chiara Camerini, Emanuela Sant’Antonio, Alessandro Ginori, Marco Pellegri, Cataldo De Gaudio, Elena Banti, Vincenzo Ciliberti, Manuela Parrini, Laura Bozzoli, Federico Simonetti, Enrico Capochiani
    Tumori, 2021
  • Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis
    Chiara Trotti, Emanuela Sant’Antonio, Daniele Vanni, Ilaria Carola Casetti, Oscar Borsani, Daniela Pietra, Virginia Valeria Ferretti, Cesare Astori, Luca Arcaini, Elisa Rumi
    Hematological Oncology, 2021
  • Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events
    Emanuela Sant'Antonio, Chiara Camerini, Vincenzo Rizzo, Caterina Musolino, Alessandro Allegra
    Clinical Lymphoma Myeloma and Leukemia, 2021
  • Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
    Alberto Alvarez-Larrán, Emanuela Sant'Antonio, Claire Harrison, Jean-Jacques Kiladjian, Martin Griesshammer, Ruben Mesa, Jean Christophe Ianotto, Francesca Palandri, Juan Carlos Hernández-Boluda, Gunnar Birgegård, Jyoti Nangalia, Steffen Koschmieder, Elisa Rumi, Tiziano Barbui
    Lancet Haematology, 2021
  • Pros and cons of the cannabinoid system in cancer: Focus on hematological malignancies
    Natasha Irrera, Alessandra Bitto, Emanuela Sant’Antonio, Rita Lauro, Caterina Musolino, Alessandro Allegra
    Molecules, 2021
  • The genetic basis of primary myelofibrosis and its clinical relevance
    Elisa Rumi, Chiara Trotti, Daniele Vanni, Ilaria Carola Casetti, Daniela Pietra, Emanuela Sant’Antonio
    International Journal of Molecular Sciences, 2020
  • Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib
    Elisa Rumi, Emanuela Sant'Antonio, Chiara Cavalloni, Giuditta Comolli, Virginia Valeria Ferretti, Irene Cassaniti, Daniela Pietra, Chiara Trotti, Michele Ciboddo, Milena Furione, Daniele Vanni, Ilaria Carola Casetti, Cristina Favaron, Fausto Baldanti, Luca Arcaini, Mario Cazzola
    Hematological Oncology, 2020
  • RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
    Giacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino, Simone Romagnoli, Niccolò Bartalucci, Enrica Ravenda, Eleonora Gelli, Emanuela Sant’Antonio, Mrinal M. Patnaik, Ayalew Tefferi, Alessandro M. Vannucchi, Paola Guglielmelli
    Blood Advances, 2020
  • The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
    Mario Tiribelli, Francesca Palandri, Emanuela Sant’Antonio, Massimo Breccia, Massimiliano Bonifacio
    Bone Marrow Transplantation, 2020
  • Myeloproliferative and lymphoproliferative disorders: State of the art
    Elisa Rumi, Claudia Baratè, Giulia Benevolo, Margherita Maffioli, Alessandra Ricco, Emanuela Sant'Antonio
    Hematological Oncology, 2020
  • Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
    Emanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, Massimo Primignani, Maria Luigia Randi, Claudia Santarossa, Elisa Rumi, Francisco Cervantes, Federica Delaini, Alessandra Carobbio, Silvia Betti, Elena Rossi, Noa Lavi, Claire N. Harrison, Natalia Curto‐Garcia, Heinz Gisslinger, Bettina Gisslinger, Giorgina Specchia, Alessandra Ricco, Nicola Vianelli, Nicola Polverelli, Maya Koren‐Michowitz, Marco Ruggeri, Francois Girodon, Martin Ellis, Alessandra Iurlo, Francesco Mannelli, Lara Mannelli, Benedetta Sordi, Giuseppe Gaetano Loscocco, Mario Cazzola, Valerio De Stefano, Tiziano Barbui, Ayalew Tefferi, Alessandro Maria Vannucchi
    American Journal of Hematology, 2020
  • Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
    Massimo Breccia, Claudia Baratè, Giulia Benevolo, Massimiliano Bonifacio, Elena Maria Elli, Paola Guglielmelli, Margherita Maffioli, Alessandra Malato, Francesco Mendicino, Giuseppe Alberto Palumbo, Novella Pugliese, Elena Rossi, Elisa Rumi, Emanuela Sant’Antonio, Alessandra Ricco, Mario Tiribelli, Francesca Palandri
    Annals of Hematology, 2020
  • A journey through infectious risk associated with ruxolitinib
    Emanuela Sant’Antonio, Massimiliano Bonifacio, Massimo Breccia, Elisa Rumi
    British Journal of Haematology, 2019
  • Facing erythrocytosis: Results of an international physician survey
    Elisa Rumi, Mary F. McMullin, Claire Harrison, Martin H. Ellis, Merav Barzilai, Nadav Sarid, Ruben Mesa, Chiara Paoli, Anna Angona, Emanuela Sant'Antonio, Virginia V. Ferretti, Chiara Cavalloni, Ilaria C. Casetti, Chiara Trotti, Tiziano Barbui
    American Journal of Hematology, 2019
  • Diagnosis and management of prefibrotic myelofibrosis
    Elisa Rumi, Emanuela Sant’Antonio, Emanuela Boveri, Daniela Pietra, Chiara Cavalloni, Elisa Roncoroni, Cesare Astori, Luca Arcaini
    Expert Review of Hematology, 2018
  • Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria
    Elisa Rumi, , Emanuela Boveri, Marta Bellini, Daniela Pietra, Virginia V. Ferretti, Emanuela Sant’Antonio, Chiara Cavalloni, Ilaria C. Casetti, Elisa Roncoroni, Michele Ciboddo, Pietro Benvenuti, Benedetta Landini, Elena Fugazza, Daniela Troletti, Cesare Astori, Mario Cazzola
    Oncotarget, 2017
  • High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists
    V De Stefano, M Ruggeri, F Cervantes, A Alvarez-Larrán, A Iurlo, M L Randi, E Elli, M C Finazzi, G Finazzi, E Zetterberg, N Vianelli, G Gaidano, E Rossi, S Betti, I Nichele, D Cattaneo, M Palova, M H Ellis, R Cacciola, A Tieghi, J C Hernandez-Boluda, E Pungolino, G Specchia, D Rapezzi, A Forcina, C Musolino, A Carobbio, M Griesshammer, E Sant’Antonio, A M Vannucchi, T Barbui
    Leukemia, 2016
  • Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
    Paola Guglielmelli, Giada Rotunno, Annalisa Pacilli, Elisa Rumi, Vittorio Rosti, Federica Delaini, Margherita Maffioli, Tiziana Fanelli, Alessandro Pancrazzi, Lisa Pieri, Rajmonda Fjerza, Daniela Pietra, Daniela Cilloni, Emanuela Sant'Antonio, Silvia Salmoiraghi, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi
    American Journal of Hematology, 2016
  • Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
    Giada Rotunno, Annalisa Pacilli, Valentina Artusi, Elisa Rumi, Margherita Maffioli, Federica Delaini, Giada Brogi, Tiziana Fanelli, Alessandro Pancrazzi, Daniela Pietra, Isabella Bernardis, Clara Belotti, Lisa Pieri, Emanuela Sant'Antonio, Silvia Salmoiraghi, Daniela Cilloni, Alessandro Rambaldi, Francesco Passamonti, Tiziano Barbui, Rossella Manfredini, Mario Cazzola, Enrico Tagliafico, Alessandro M. Vannucchi, Paola Guglielmelli
    American Journal of Hematology, 2016
  • Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
    D Pietra, E Rumi, V V Ferretti, C A Di Buduo, C Milanesi, C Cavalloni, E Sant'Antonio, V Abbonante, F Moccia, I C Casetti, M Bellini, M C Renna, E Roncoroni, E Fugazza, C Astori, E Boveri, V Rosti, G Barosi, A Balduini, M Cazzola
    Leukemia, 2016
  • Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia
    E. Rumi, I. Bertozzi, I. C. Casetti, E. Roncoroni, C. Cavalloni, M. Bellini, E. Sant'Antonio, M. Gotti, V. V. Ferretti, C. Milanesi, E. Peroni, D. Pietra, C. Astori, M. L. Randi, M. Cazzola, on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
    Haematologica, 2015
  • Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
    Elisa Rumi, Daniela Pietra, Cristiana Pascutto, Paola Guglielmelli, Alejandra Martínez-Trillos, Ilaria Casetti, Dolors Colomer, Lisa Pieri, Marta Pratcorona, Giada Rotunno, Emanuela Sant’Antonio, Marta Bellini, Chiara Cavalloni, Carmela Mannarelli, Chiara Milanesi, Emanuela Boveri, Virginia Ferretti, Cesare Astori, Vittorio Rosti, Francisco Cervantes, Giovanni Barosi, Alessandro M. Vannucchi, Mario Cazzola
    Blood, 2014
  • CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis
    Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra, Jelena D. Milosevic, Ilaria C. Casetti, Marta Bellini, Nicole C. C. Them, Chiara Cavalloni, Virginia V. Ferretti, Chiara Milanesi, Tiina Berg, Emanuela Sant’Antonio, Emanuela Boveri, Cristiana Pascutto, Cesare Astori, Robert Kralovics, Mario Cazzola
    Blood, 2014
  • JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
    Elisa Rumi, Daniela Pietra, Virginia Ferretti, Thorsten Klampfl, Ashot S. Harutyunyan, Jelena D. Milosevic, Nicole C. C. Them, Tiina Berg, Chiara Elena, Ilaria C. Casetti, Chiara Milanesi, Emanuela Sant’Antonio, Marta Bellini, Elena Fugazza, Maria C. Renna, Emanuela Boveri, Cesare Astori, Cristiana Pascutto, Robert Kralovics, Mario Cazzola
    Blood, 2014
  • Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
    Elisa Rumi, Daniela Pietra, Paola Guglielmelli, Roberta Bordoni, Ilaria Casetti, Chiara Milanesi, Emanuela Sant’Antonio, Virginia Ferretti, Alessandro Pancrazzi, Giada Rotunno, Marco Severgnini, Alessandro Pietrelli, Cesare Astori, Elena Fugazza, Cristiana Pascutto, Emanuela Boveri, Francesco Passamonti, Gianluca De Bellis, Alessandro Vannucchi, Mario Cazzola
    Blood, 2013
  • Somatic mutations of calreticulin in myeloproliferative neoplasms
    Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan, Harini Nivarthi, Elisa Rumi, Jelena D. Milosevic, Nicole C.C. Them, Tiina Berg, Bettina Gisslinger, Daniela Pietra, Doris Chen, Gregory I. Vladimer, Klaudia Bagienski, Chiara Milanesi, Ilaria Carola Casetti, Emanuela Sant'Antonio, Virginia Ferretti, Chiara Elena, Fiorella Schischlik, Ciara Cleary, Melanie Six, Martin Schalling, Andreas Schönegger, Christoph Bock, Luca Malcovati, Cristiana Pascutto, Giulio Superti-Furga, Mario Cazzola, Robert Kralovics
    New England Journal of Medicine, 2013
  • Novel therapeutic strategies in multiple myeloma: Role of the heat shock protein inhibitors
    Alessandro Allegra, Emanuela Sant’Antonio, Giuseppa Penna, Andrea Alonci, Arianna D’Angelo, Sabina Russo, Antonino Cannavò, Demetrio Gerace, Caterina Musolino
    European Journal of Haematology, 2011
  • Epigenetic therapy in myelodysplastic syndromes
    Caterina Musolino, Emanuela Sant’Antonio, Giuseppa Penna, Andrea Alonci, Sabina Russo, Angela Granata, Alessandro Allegra
    European Journal of Haematology, 2010

RECENT SCHOLAR PUBLICATIONS

  • CLINICAL AND GENOMIC PATTERNS OF DISEASE PROGRESSION IN CLL PATIENTS TREATED WITH FIXED-DURATION VERSUS CONTINUOUS TARGETED THERAPIES
    A Serafin, F Angotzi, A Bevilacqua, A Cellini, M D'Antiga, L Bonaldi, ...
    Haematologica 111 (1), 1-1 , 2026
    2026
  • Monoclonal B‐cell lymphocytosis: the silent clone the haematologists should not neglect
    A Serafin, E Sant’Antonio, F Mavilia, F Gandini, S De Pretis, L Scarfò, ...
    Hematological Oncology 43, e70084 , 2025
    2025
    Citations: 2
  • Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and …
    GM Rigolin, A Urso, S Soddu, R Moia, R Dondolin, A Olivieri, I Scortechini, ...
    Blood 144, 1872 , 2024
    2024
  • Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless …
    A Campanella, A Capasso, S Heltai, C Taccetti, E Albi, Y Herishanu, ...
    American Journal of Hematology 99 (4), 745-750 , 2024
    2024
    Citations: 15
  • Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax+/-Ibrutinib: Results of the Improve Study
    E Albi, L Scarfo, S Heltai, E Scarano, L Schiattone, L Farina, R Moia, ...
    Blood 142, 6521 , 2023
    2023
    Citations: 3
  • P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN …
    A Campanella, A Capasso, C Taccetti, S Heltai, E Albi, Y Herishanu, ...
    HemaSphere 7 (S3), e483427a , 2023
    2023
  • P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX+/-IBRUTINIB: THE IMPROVE STUDY COHORT
    L Scarfò, S Heltai, E Albi, E Scarano, L Schiattone, L Farina, R Moia, ...
    HemaSphere 7 (S3), e8082529 , 2023
    2023
    Citations: 3
  • Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
    G Coltro, E Sant'Antonio, GA Palumbo, F Mannelli, V De Stefano, ...
    Cancer Medicine 12 (7), 8166-8171 , 2023
    2023
    Citations: 15
  • Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL”(regional Tuscan lymphoma network)
    E Cencini, I Romano, F Ghio, C Camerini, I Bertaggia, R Giachetti, ...
    Annals of Hematology 102 (4), 841-849 , 2023
    2023
    Citations: 6
  • Germline Predisposition in the Field of Myeloproliferative Neoplasms
    E Sant’Antonio, O Borsani, E Rumi
    Hematological Cancer Pathophysiology: An Interdisciplinary Approach, 143-158 , 2022
    2022
  • Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
    P Guglielmelli, FI Vanderwert, S Romagnoli, G Coltro, GG Loscocco, ...
    Blood, The Journal of the American Society of Hematology 140 (Supplement 1 … , 2022
    2022
    Citations: 1
  • CLL-461 humoral response to COVID-19 vaccine: a challenge in CLL
    A Capasso, E Albi, L Schiattone, F Martini, E Sant'Antonio, L Scarfò, ...
    Clinical Lymphoma Myeloma and Leukemia 22, S279-S280 , 2022
    2022
    Citations: 2
  • Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
    A Capasso, E Albi, L Schiattone, F Martini, E Sant'Antonio, L Scarfò, ...
    Clinical Lymphoma, Myeloma & Leukemia 22, S143 , 2022
    2022
  • Management of myelofibrosis during treatment with ruxolitinib: a real-world perspective in case of resistance and/or intolerance
    M Breccia, F Palandri, P Guglielmelli, GA Palumbo, A Malato, F Mendicino, ...
    Current Oncology 29 (7), 4970-4980 , 2022
    2022
    Citations: 4
  • Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms
    D Vanni, O Borsani, Y Nannya, E Sant'Antonio, C Trotti, IC Casetti, ...
    EJHaem 3 (2), 475-479 , 2022
    2022
    Citations: 1
  • Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
    O Borsani, P Bastard, J Rosain, A Gervais, E Sant’Antonio, D Vanni, ...
    Blood, The Journal of the American Society of Hematology 139 (17), 2716-2720 , 2022
    2022
    Citations: 6
  • New Insights into Neuropeptides Regulation of the Immune System and Hemopoiesis: Effects on Hematologic Malignancies
    A Allegra, E Sant’Antonio, C Musolino, R Ettari
    Current Medicinal Chemistry 29 (14), 2412-2437 , 2022
    2022
  • Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: a critical discussion of unmet medical needs, with a focus on pregnancy
    E Sant'Antonio, O Borsani, C Camerini, C Botta, M Santoro, A Allegra, ...
    Blood Reviews 52, 100903 , 2022
    2022
    Citations: 4
  • Unusual presentation of extranodal diffuse large B-cell lymphoma in a solid-organ recipient during long-term immunosuppressive treatment
    C Camerini, E Sant’Antonio, A Ginori, M Pellegri, C De Gaudio, E Banti, ...
    Tumori Journal 107 (6), NP127-NP130 , 2021
    2021
  • Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms
    O Borsani, P Bastard, J Rosain, A Gervais, E Sant'Antonio, D Vanni, ...
    Blood 138, 3587 , 2021
    2021

MOST CITED SCHOLAR PUBLICATIONS

  • Somatic mutations of calreticulin in myeloproliferative neoplasms
    T Klampfl, H Gisslinger, AS Harutyunyan, H Nivarthi, E Rumi, JD Milosevic, ...
    New England Journal of Medicine 369 (25), 2379-2390 , 2013
    2013
    Citations: 2654
  • JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
    E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, ...
    Blood, The Journal of the American Society of Hematology 123 (10), 1544-1551 , 2014
    2014
    Citations: 821
  • Clinical effect of driver mutations of JAK2 , CALR , or MPL in primary myelofibrosis
    E Rumi, D Pietra, C Pascutto, P Guglielmelli, A Martínez-Trillos, I Casetti, ...
    Blood, The Journal of the American Society of Hematology 124 (7), 1062-1069 , 2014
    2014
    Citations: 534
  • Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
    D Pietra, E Rumi, VV Ferretti, CA Di Buduo, C Milanesi, C Cavalloni, ...
    Leukemia 30 (2), 431-438 , 2016
    2016
    Citations: 361
  • Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL -mutated myeloproliferative neoplasms
    E Rumi, D Pietra, P Guglielmelli, R Bordoni, I Casetti, C Milanesi, ...
    Blood, The Journal of the American Society of Hematology 121 (21), 4388-4395 , 2013
    2013
    Citations: 132
  • High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
    V De Stefano, M Ruggeri, F Cervantes, A Alvarez-Larrán, A Iurlo, ...
    Leukemia 30 (10), 2032-2038 , 2016
    2016
    Citations: 111
  • Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group
    G Rotunno, A Pacilli, V Artusi, E Rumi, M Maffioli, F Delaini, G Brogi, ...
    American journal of hematology 91 (7), 681-686 , 2016
    2016
    Citations: 111
  • CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis
    E Rumi, AS Harutyunyan, D Pietra, JD Milosevic, IC Casetti, M Bellini, ...
    Blood, The Journal of the American Society of Hematology 123 (15), 2416-2419 , 2014
    2014
    Citations: 106
  • RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
    G Coltro, G Rotunno, L Mannelli, C Mannarelli, S Fiaccabrino, ...
    Blood advances 4 (15), 3677-3687 , 2020
    2020
    Citations: 89
  • Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases
    E Sant'Antonio, P Guglielmelli, L Pieri, M Primignani, ML Randi, ...
    American journal of hematology 95 (2), 156-166 , 2020
    2020
    Citations: 83
  • Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria
    E Rumi, E Boveri, M Bellini, D Pietra, VV Ferretti, E Sant’Antonio, ...
    Oncotarget 8 (60), 101735 , 2017
    2017
    Citations: 81
  • Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
    P Guglielmelli, G Rotunno, A Pacilli, E Rumi, V Rosti, F Delaini, M Maffioli, ...
    American journal of hematology 91 (9), 918-922 , 2016
    2016
    Citations: 77
  • Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
    A Allegra, E Sant’Antonio, G Penna, A Alonci, A D’Angelo, S Russo, ...
    European journal of haematology 86 (2), 93-110 , 2011
    2011
    Citations: 55
  • Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia
    E Rumi, I Bertozzi, IC Casetti, E Roncoroni, C Cavalloni, M Bellini, ...
    Haematologica 100 (11), e443 , 2015
    2015
    Citations: 52
  • Epigenetic therapy in myelodysplastic syndromes
    C Musolino, E Sant’Antonio, G Penna, A Alonci, S Russo, A Granata, ...
    European journal of haematology 84 (6), 463-473 , 2010
    2010
    Citations: 47
  • A journey through infectious risk associated with ruxolitinib
    E Sant’Antonio, M Bonifacio, M Breccia, E Rumi
    British Journal of Haematology 187 (3), 286-295 , 2019
    2019
    Citations: 44
  • The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
    M Tiribelli, F Palandri, E Sant’Antonio, M Breccia, M Bonifacio
    Bone Marrow Transplantation 55 (4), 708-716 , 2020
    2020
    Citations: 41
  • Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
    A Alvarez-Larrán, E Sant'Antonio, C Harrison, JJ Kiladjian, ...
    The Lancet Haematology 8 (9), e658-e665 , 2021
    2021
    Citations: 34
  • The genetic basis of primary myelofibrosis and its clinical relevance
    E Rumi, C Trotti, D Vanni, IC Casetti, D Pietra, E Sant’Antonio
    International Journal of Molecular Sciences 21 (23), 8885 , 2020
    2020
    Citations: 31
  • Diagnosis and management of prefibrotic myelofibrosis
    E Rumi, E Sant’Antonio, E Boveri, D Pietra, C Cavalloni, E Roncoroni, ...
    Expert review of hematology 11 (7), 537-545 , 2018
    2018
    Citations: 27